Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Summary
HR6610 would mandate NADAC-based reimbursement and point-of-sale rebate passthrough for PBMs in federal employee health plans. The bill is early-stage with 32 cosponsors and bipartisan sponsorship. Direct financial impact on UNH, CI, and HUM is limited to a small book of business, but the legislation signals growing bipartisan appetite for PBM pricing reform that could expand to larger markets.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6610 mandates NADAC-based reimbursement and rebate passthrough, directly compressing PBM margins on federal employee health plans
- 2.Current early-stage status (referred to committee, no hearings) limits near-term market impact; bill has low probability of passage in the 119th Congress without further momentum
- 3.Bipartisan sponsorship, including House Oversight Committee Chairman Comer, signals growing legislative appetite for broader PBM reform that could expand to Medicare Part D or commercial insurance
- 4.Real market data shows UNH +36.34%, CI +9.35%, HUM +38.19% over the past 30 days — unrelated to this bill, driven by broader market trends
Market Implications
UNH ($368.92), CI ($291.70), and HUM ($239.61) have rallied sharply over the past 30 days — UNH up 36.34%, CI up 9.35%, and HUM up 38.19% — primarily driven by broader market tailwinds, not PBM reform sentiment. The FEHBP-specific mandate in HR6610 is too narrow to explain these moves. Investors should treat this 4/10 impact score bill as a watch item: if the Oversight Committee schedules a markup or a Senate companion bill is introduced, the bearish case for UNH, CI, and HUM strengthens considerably. The market is currently pricing in zero probability of PBM reform passage. Any legislative progress would introduce downside risk to the PBM-heavy revenue streams of these stocks.
Full Analysis
On December 11, 2025, Representative Auchincloss (D-MA) introduced HR6610, the Pharmacists Fight Back in Federal Employee Health Benefit Plans Act, with 32 cosponsors including Rep. Comer (R-KY), chairman of the House Oversight Committee. The bill was referred to the House Committee on Oversight and Government Reform and has no further action history — it remains in early legislative stages. The bill amends 5 U.S.C. §8904 to require all FEHBP health plans to mandate that their PBMs reimburse in-network pharmacies at the National Average Drug Acquisition Cost (NADAC) plus the lesser of 4% or $50, plus the state Medicaid dispensing fee. It also requires PBMs to pass 100% of manufacturer rebates through to patients at the point of sale by reducing coinsurance/copayments. There is no funding authorization — this is a regulatory mandate, not a spending bill. The three largest publicly traded PBMs — OptumRx ($UNH), Express Scripts ($CI), and Humana Pharmacy Solutions ($HUM) — administer prescription drug benefits for FEHBP plans. Under current practice, PBMs negotiate reimbursements below NADAC and retain a portion of manufacturer rebates as profit. HR6610 would eliminate both profit levers on the FEHBP book. However, FEHBP represents a small fraction of total PBM claims volume — the commercial market, Medicare Part D, and state Medicaid programs are far larger. The immediate financial impact on UNH, CI, and HUM is limited to tens-to-hundreds of millions annually — not a material earnings event for companies with $100B+ (UNH), $50B+ (CI), and $40B+ (HUM) in revenues. The real risk is precedent: bipartisan support for PBM reform, including the Oversight Committee chairman, signals that similar mandates could be proposed for Medicare Part D and commercial plans in future sessions. Over the trailing 30 days through April 30, 2026, UNH is up 36.34%, CI up 9.35%, and HUM up 38.19% — primarily driven by broader market and sector trends rather than this early-stage bill. The next legislative step is committee markup in the House Oversight Committee, which has not been scheduled. Without a Senate companion bill or committee action, the probability of passage in the 119th Congress remains low. Investors should monitor whether Chairman Comer advances the bill and whether a Senate version emerges — those events would materially increase the bearish thesis for large-cap PBMs.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Mandatory pricing: PBM must reimburse in-network pharmacies at NADAC + 4% or $50 (whichever is less) plus state Medicaid dispensing fee, and pass manufacturer rebates through to patients at point-of-sale.
Who must act
OptumRx, the PBM division of UnitedHealth Group (UNH), administering prescription drug benefits for FEHBP plans.
What happens
OptumRx loses ability to negotiate below-NADAC reimbursement rates and retain manufacturer rebates as profit on the FEHBP book of business, compressing per-claim gross margin on federal employee plans.
Stock impact
OptumRx's FEHBP segment faces direct margin compression; however FEHBP is a small fraction of Optum's total PBM revenue (majority is commercial, Medicare Part D, and state Medicaid). Near-term earnings impact is minimal unless the bill expands to other markets.
What the bill does
Mandatory pricing: PBM must reimburse in-network pharmacies at NADAC + 4% or $50 (whichever is less) plus state Medicaid dispensing fee, and pass manufacturer rebates through to patients at point-of-sale.
Who must act
Express Scripts, the PBM division of The Cigna Group (CI), administering prescription drug benefits for FEHBP plans.
What happens
Express Scripts loses ability to negotiate below-NADAC reimbursement rates and retain manufacturer rebates as profit on the FEHBP book of business, compressing per-claim gross margin on federal employee plans.
Stock impact
Express Scripts' FEHBP segment faces direct margin compression; similar to UNH, FEHBP is a small portion of Express Scripts' total book. The bill is early-stage with low immediate financial risk, but sets a legislative template that could expand to commercial and Medicare markets.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Pharmacists Fight Back in Medicare and Medicaid Act
PBM FAIR Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →